Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trialSi‐Yang Maggie Liu, Yi‐Long Wu, Xiaorong Dong et al.|EClinicalMedicine|2023Cited by 11
Genomic and immune characteristics of <i>HER2</i>‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapyHai‐Yan Tu, Yi‐Long Wu, Mei-Mei Zheng et al.|Molecular Oncology|2023Cited by 9
Efficacy, Safety and Dose Selection of AZD3759 in Patients with Untreated <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer and Central Nervous System Metastases in a Phase 2, Multi-Center, Umbrella Trial (CTONG1702)Si‐Yang Maggie Liu, Yi‐Long Wu, Xiaorong Dong et al.|SSRN Electronic Journal|2023Cited by 0